Modulation of Human Multidrug Resistance Proteins by Reactive Quinone-based Glutathione Conjugates

dc.contributor.authorSlot, Andrew Johannesen
dc.contributor.departmentPathology and Molecular Medicineen
dc.contributor.supervisorCole, Susan P. C.en
dc.date2011-06-03 10:00:36.484's University at Kingstonen
dc.descriptionThesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2011-06-03 10:00:36.484en
dc.description.abstractThe multidrug resistance protein 1 (MRP1) and MRP2 mediate the ATP-dependent cellular efflux of a diverse set of organic molecules including many glutathione (GSH) conjugates. In the present study, a series of GSH conjugated quinones (some of which have been shown to be toxic) were investigated for their ability to interact with human MRP1 and MRP2 using membrane vesicles enriched for these transporters.Several structurally and biologically distinct classes of endogenous (e.g. estradiol) and exogenous (e.g. hydroquinone (HQ),N-methyl-α-methyldopamine (N-Me-α-MeDA), and caffeic acid (CA)) GSH conjugated metabolites inhibited both MRP1- and MRP2-mediated vesicular transport of the prototypic MRPsubstrate (17β-estradiol-17β-D-glucuronide (E217βG)). The relative inhibitory potencies of the metabolites with respect to MRP1 versus MRP2 differed by approximately 10-fold, with the exception of4-hydroxy-2-(glutathion-S-yl)-17β-estradiol (4-OH-2-GS-E2), which differed by 300-fold. The catechol estradiols, N-Me-α-MeDA, and CA metabolites competitively inhibited MRP1-mediated E217βG transport and thus, are potential substrates for this transporter. The estradiol metabolites 2-hydroxy-1-(glutathion-S-yl)-17β-estradiol(2-OH-1-GS-E2) and 4-OH-2-GS-E2were bothsubsequently shown to besubstrates of MRP1 and MRP2by means ofa substrate depletion assay and a vesicular accumulation assay using HPLC with electrochemical detection. Transport of 2-OH-1-GS-E2 by MRP1 was inhibited by several MRP1 substrates (e.g. E217βG, leukotriene C4, and GSH disulfide) and modulators (e.g. MK571 and S-decyl-GSH). The chemically reactiveGSH-conjugated HQ metabolites also inhibited MRP1-mediated vesicular transport of E217βGwith IC50values ranging from 3 – 30 μM. To determine whether these compounds might modify MRP1, MRP1-enriched membrane vesicles were incubated with 2,5-(glutathion-S-yl)-hydroquinone (2,5-GS-HQ) and then immunoblotted with a MRP1-specific monoclonal antibody.An apparentreduction in the electrophoretic mobility of immuno-reactive bands relative to untreated vesicles was observed. However, subsequent limited trypsin digests did not show any differences in the digestion profiles between 2,5-GS-HQ-treated and control vesicles, suggesting no significant differences in protein structure with respect to accessible trypsin cleavage sites. Further experiments are needed to demonstrateMRP1 adduction by 2,5-GS-HQ.In conclusion, the data presented here are the first to show that reactive GSH-conjugated catechol and quinone metabolites can be substrates and modulators of MRP1 and MRP2 in vitro.en
dc.relation.ispartofseriesCanadian thesesen
dc.rightsThis publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.en
dc.subjectMultidrug Resistance Proteinen
dc.titleModulation of Human Multidrug Resistance Proteins by Reactive Quinone-based Glutathione Conjugatesen
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
2.67 MB
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
1.72 KB
Item-specific license agreed upon to submission